阿考曲蒙滴眼液0.003%治疗干眼体征与症状:3期关键性COMET-2与COMET-3研究结果
两项相同的随机、多中心、双盲、赋形剂对照3期研究纳入30岁及以上干眼患者(COMET-2 N=465,COMET-3 N=466),按1:1随机接受阿考曲蒙0.003%或赋形剂每日两次共90天。主要终点第14天无麻醉Schirmer试验评分增加≥10 mm的比例在两项研究中均达成(COMET-2 42.6% vs 8.2%;COMET-3 53.2% vs 14.4%;P均<0.0001)。
要点
- 第14天无麻醉Schirmer试验增加≥10 mm的比例阿考曲蒙组高于赋形剂组(两项研究P均<0.0001)。
- 泪液产生增加从第1天持续至第90天,两项研究均P<0.0001。
- 第28天全球SANDE评分降低在两项研究中均利于阿考曲蒙,COMET-2达统计学显著。
核心结论
- 在COMET-2和COMET-3中,与赋形剂相比,阿考曲蒙带来一致的、有临床意义的泪液产生增加及干眼体征和症状的减轻。
研究设计与样本
- 两项相同的随机、多中心、双盲、赋形剂对照3期研究。
- 纳入30岁及以上成人干眼患者,至少1眼总角膜荧光素染色(tCFS)评分≥2且≤15(无区域评分<3)、麻醉Schirmer试验评分≥2且<10 mm/5 min,且眼不适视觉模拟量表与干眼症状评估(SANDE)评分均≥50。
- 患者(COMET-2 N=465;COMET-3 N=466)按1:1随机接受阿考曲蒙0.003%或赋形剂每日两次共90天(ClinicalTrials.gov标识:COMET-2 NCT05285644;COMET-3 NCT05360966)。
主要发现
- 主要终点第14天无麻醉Schirmer试验评分增加≥10 mm的比例:COMET-2阿考曲蒙组42.6% vs 赋形剂组8.2%;COMET-3阿考曲蒙组53.2% vs 赋形剂组14.4%;两项研究P均<0.0001。
- 第28天全球SANDE评分较基线变化(关键次要终点)在两项研究中均利于阿考曲蒙,且在COMET-2达统计学显著。
- 泪液产生增加从第1天至第90天均利于阿考曲蒙 vs 赋形剂,两项研究P均<0.0001。
- 第28天和第90天tCFS及所有时间点总结膜染色在阿考曲蒙组观察到更大降低。
- 仅有轻度滴眼部位烧灼/刺痛这一眼部不良事件发生率超过2.5%。
关键数值与推荐
- 主要终点:第14天无麻醉Schirmer试验评分增加≥10 mm的患者比例(COMET-2 42.6% vs 8.2%;COMET-3 53.2% vs 14.4%;P均<0.0001)。
- 关键次要终点:第28天全球SANDE评分较基线变化,两项研究均利于阿考曲蒙,COMET-2达统计学显著。
- 其他次要终点:第1天和第90天无麻醉Schirmer试验较基线变化。
- 探索性终点:tCFS和总结膜染色较基线变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the safety and efficacy of the transient receptor potential melastatin 8 agonist acoltremon on signs and symptoms of dry eye disease (DED). DESIGN: Two identical randomized, multicenter, double-masked, vehicle-controlled phase 3 studies. PARTICIPANTS: Adults aged 30 years or older with a DED diagnosis, at least 1 eye with both total corneal fluorescein staining (tCFS) score of 2 or more and 15 or less (no region scoring less than 3) and anesthetized Schirmer test score of 2 or more and less than 10 mm/5 min, and both ocular discomfort (visual analog scale) and Symptom Assessment iN Dry Eye (SANDE) scores of 50 or more. METHODS: Patients (COMET-2, N = 465; COMET-3, N = 466) were randomized 1:1 to acoltremon 0.003% (ACO) or vehicle twice daily for 90 days (ClinicalTrials.gov identifiers: COMET-2, NCT05285644; COMET-3, NCT05360966). MAIN OUTCOME MEASURES: The primary end point was the proportion of patients achieving a 10-mm or greater increase in unanesthetized Schirmer test (UST) score on day 14. The key secondary end point was change from baseline (CFB) in global SANDE score on day 28. Additional secondary end points included CFB in UST on days 1 and 90. Exploratory end points included CFB in tCFS and total conjunctival staining. RESULTS: The primary end point was met in both studies, with more patients receiving ACO achieving a 10-mm or greater increase in UST on day 14 (ACO vs. vehicle: COMET-2, 42.6% vs. 8.2%; COMET-3, 53.2% vs. 14.4%; P < 0.0001 for both). Reduction in global SANDE score by day 28 (key secondary end point) favored ACO in both studies, and was statistically significant in COMET-2. Increased tear production favored ACO versus vehicle as early as day 1 through day 90 in both studies (P < 0.0001). Greater reductions with ACO were observed in tCFS on days 28 and 90 and in total conjunctival staining at all time points. Mild instillation-site burning/stinging was the only ocular adverse event reported with an incidence of more than 2.5%. CONCLUSIONS: In COMET-2 and COMET-3, ACO compared with vehicle led to consistent, clinically meaningful tear production and reductions in DED signs and symptoms. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Pattar GR, Wirta D, Jerkins G, et al. Acoltremon Ophthalmic Solution 0.003% for Signs and Symptoms of Dry Eye Disease: Results of Phase 3 Pivotal COMET-2 and COMET-3 Studies. Ophthalmology. 2025. PMID: 41038456. doi:10.1016/j.ophtha.2025.09.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。